The chvA gene product of Agrobacterium tumefaciens is required for virulence and attachment of bacteria to plant cells. Three chvA mutants were studied. In vivo, they were defective in the synthesis, accumulation, and secretion of 0-(1-2)glucan; however, the 235-kilodalton (kDa) protein known to be involved in the synthesis of P-(1-2)glucan (A. Zorreguieta and R. Ugalde, J. Bacteriol. 167:947-951, 1986) was present and active in vitro.
The integration of a segment of Agrobacterium tumefaciens tumor-inducing (Ti) plasmid DNA into the plant genome results in crown gall tumor formation on dicotyledonous plants (19, 22) . This process requires a number of plasmid Ti and chromosomal virulence genes (9) . Chromosomal virulence loci chvA and chvB are required for attachment of bacteria to plant cells (6, 9) . chvA and chvB have homologous and functionally interchangeable counterparts in Rhizobium meliloti, in which they are required for effective nodulation of alfalfa (7, 10) . Avirulent A. tumefaciens chvB mutants do not form in vivo (20) or in vitro (30) cyclic 3-(1-2)glucan. The same phenotype was described for an R. meliloti mutant (10) . The chvB region, as defined phenotypically, partly encodes a 235-kilodalton (kDa) inner membrane-bound protein required as an intermediate in 3-(1-2)glucan synthesis (28, 30, 31) . The 235-kDa structural protein gene extends 3.5 kilobases downstream from the phenotypically defined chvB region. Mutants with insertions in this 3.5-kilobase DNA region are virulent and form truncated proteins that are active in the 3-(1-2)glucan synthesis (28) , which demonstrates that only the part of the chvB locus necessary for ,B-(1-2)glucan synthesis is required for effective plant infection. This glucan has been observed only in Agrobacterium and Rhizobium species (24) and is believed to play a central role in the interaction of these bacteria with plants, since in both genera, mutants affected in synthesis of the glucan are avirulent or form ineffective empty nodules. Agrobacterium chvA DNA contains a 1.8-kilobase open reading frame coding for a protein similar to an Escherichia coli hemolysin export protein (HlyB). The protein also has homology to HisP, MalK, and OppD transport proteins (3, 11) . The R. meliloti ndvA (the equivalent of A. tumefaciens chvA) DNA nucleotide sequence was recently determined, with results very similar to those obtained for the A. tumefaciens gene; this finding suggests a very conserved function for the gene products (23) . It has been proposed that ndvA (23) and chvA (3) are involved in the excretion of cyclic 3-(1-2)glucan. In this study, we further characterized A. tumefaciens chvA mutants at the biochemical level and found that although they have increased levels of the 235-kDa 3-(1-2)glucan intermediate protein, they are defective in vivo in the synthesis and secretion of P-(1-2)glucan and accumulate an altered molecular form of cellular -(1-2) glucan.
MATERIALS AND METHODS
Bacterial strains, plasmids, and media. The A. tumefaciens strains and plasmids used are listed in Table 1 . Bacteria were grown on tryptone-yeast extract (TY) medium (30) . Carbenicillin or kanamycin was added to a final concentration of 100 p.gIml. Merodiploid strains for complementation analysis were obtained by triparental mating as described previously (5) . Transconjugants were selected on AB agar medium (6) with the appropriate antibiotic and were purified from E. coli by being streaked five times on selective media.
Isolation of 0-(1-2)glucan from cells. Cells from 100-ml cultures were harvested by centrifugation at 10,000 x g for 10 min. Pellets were extracted with 10% trichloroacetic acid (TCA) for 30 min at room temperature as described previously (17) . TCA extracts were neutralized with ammonium hydroxide, concentrated, and subjected to gel filtration on Bio-Gel P4 columns (78 by 1.8 cm; Bio-Rad Laboratories, Richmond, Calif.). Columns were eluted with 0.1 M pyridine-acetate buffer (pH 5.5). Fractions of 1.5 ml were collected, and carbohydrates were detected by the anthrone- Acid hydrolysis and paper chromatography. Partial acid hydrolysis of the glucan was carried out in 0.5 N HC1 at 100°C for 20 to 30 min; total acid hydrolysis was carried out in 1 N HCI at 100°C for 4 h. HCI was removed by evaporation under an air stream, and the hydrolysates were subjected to descending paper chromatography on Whatman no. 1 paper (Whatman, Inc., Clifton, N.J.) with solvent A (butanol-pyridine-water [6:4:3] ) or solvent B (isopropanolacetic acid-water [27:4:9] ). Sugars were detected by the alkaline-silver method (26) . DEAE-Sephadex chromatography. Materials applied to DEAE-Sephadex A-25 columns (6 by 0.8 cm; Pharmacia Fine Chemicals, Piscataway, N.J.) were batch eluted with 6 ml of water and with 6 ml each of 10, 50, 100, 200, and 500 mM NaCl. Fractions of 1.5 ml were collected.
Chemical treatments. 1-(1-2)Glucan recovered from the Bio-Gel P4 columns was successively treated with HCl (10 mM) at 100°C for 90 min and with NaOH (0.5 M) at 100°C for 80 min as previously described for removing polysaccharide nonsugar substituents (14, 18) .
In vivo synthesis of 0-(1-2)glucan. Overnight cultures (1.5 ml) grown in yeast extract-mannitol medium (27) were centrifuged (15 min at 2,200 x g), and cells were washed once with 5 ml of M9 medium minus glucose (15) . Cells suspended in 0.5 ml of M9 medium minus glucose but containing 30 ,uCi of [14C]glucose (381 mCi/mmol) were incuhated for 10 min at 28°C. Cells and supematants were separated by centrifugation (2 min in an Eppendorf centrifuge), and cell pellets were extracted with 10% TCA for 30 min at room temperature. TCA extracts and supernatants were subjected to gel chromatography on Bio-Gel P4 columns as described above for the isolation of P-(1-2)glucan.
Preparation of inner membranes and in vitro 13-(1-2)glucan synthesis. Inner membranes were purified as described previously (31) . In vitro synthesis of P-(1-2)glucan, polyacryl- amide gel electrophoresis of inner membrane proteins, and fluorography were carried out as described previously (30) .
Incubation with Glusulase and ,-galactosidase assay. Glusulase treatments were carried out as described previously (29) . Assay of P-galactosidase was performed as described elsewhere (16) after 10 min at 10°C, reactions were stopped by addition of 0.5 ml of 10% TCA. The precipitates were subjected to polyacrylamide gel electrophoresis and fluorography as described elsewhere (30 (7, 23) , neither secreted nor accumulated cellular P-(1-2)glucan; however, it was previously reported that an A. tiumefaciens chvA mutant produced ,B-(1-2)glucan (20) . To clarify this controversy, we studied the accumulation, secretion, and in vivo and in vitro synthesis of P-(1-2)glucan in three chvA mutants.
Accumulation of cellular 0-(1-2)glucan. such as sn-i phosphoglycerol (1, 18) , succinate (13) , methyl malonate (13), or pyruvate (12) , that have been reported to be present in ,-(1-2)glucan. Type II P-(1-2)glucan eluted from the Bio-Gel P4 column with the same Kav as did the most abundant 3-(1-2)glucan obtained in vitro with purified inner membranes ( Fig. 2A) . Figures 2B and C show the elution profiles of type I P-(1-2)glucan recovered from strains A348 and ME42, respectively. ME42 type I P-(1-2)glucan treated with alkali and acid yielded a type II P-(1-2)glucan, as judged by its elution volume from the Bio-Gel P4 column (Fig. 2D) . DEAE-Sephadex chromatography of this treated type I P-(1-2)glucan showed that 100% became neutral.
Alkaline and acid treatments did not break the P-(1-2)-glycosidic linkage because the sensitivity to Glusulase did not change after these treatments (29) . On the other hand, type II 3-(1-2)glucan recovered from the ME42 mutant and treated in the same way did not change its elution volume from the Bio-Gel P4 column. Thus, type I and type II 3-(1-2)glucans differed in modification with nonsugar substituents that could be removed by alkaline and acid treatments; in addition, type II ,B-(1-2)glucan was indistinguishable by Bio-Gel P4 chromatography from 3-(1-2)glucan obtained in vitro with purified inner membranes.
In vivo synthesis of P-(1-2)glucan. To study the rate of synthesis of P-(1-2)glucan, growing cultures were incubated for short periods of time with [14C]glucose as described in Materials and Methods. After 10 min of incubation, cells were spun down, the supernatants were recovered, and the cells were extracted with 10% TCA. Supernatants and TCA extracts were subjected to gel chromatography on Bio-Gel P4 columns (Fig. 3) . TCA extracts of A. tumefaciens wild-type strain A348 and mutant strains ME42 and ME104 contained type II ,B-(1-2)glucan and a small amount of type I ,B-(1-2)glucan (Fig.  3A to C) . The wild-type A348 culture supernatant contained type I 3-(1-2)glucan; remarkably, no type II 3-(1-2)glucan was observed (Fig. 3D) . On the other hand, mutant supernatants did not contain type I ,B-(1-2)glucan ( Fig. 3E and F) , but a small amount of type II P-(1-2)glucan was detected. The rate of synthesis of the two types of ,B-(1-2)glucan is shown in Table 3 . Wild-type cells formed type I 3-(1-2)glucan at a rate 100 times higher than that of chvA mutants of strain ME42 or ME104. In addition to having a low rate of synthesis, the mutants were totally defective in secretion into the culture supernatant of type I P-(1-2)glucan (Table 3 and Fig. 3) . Thus, the synthesis of type I P-(1-2)glucan was strongly reduced in chvA mutants, but an increase in the rate of synthesis of type II was observed ( (Fig. 4) . Neutral glucans resistant to degradation with Glusulase, which sugd that they had a cyclic structure. Glusulase was active leasing glucose from partially acid-hydrolyzed 1-(1-ican, whereas native ,B-(1-2)glucan was insensitive to effect (29) .
vitro synthesis of P- (1-2) Fig. SB and D) . This result indicates that the mutant protein intermediate was active in the synthesis of ,-(1-2)glucan.
3-(1-2)glucans obtained in vitro were subjected to gel chromatography on a Bio-Gel P4 column. The most abundant P-(1-2)glucan obtained in vitro eluted with a Kav of 0.25 ( Fig.   2A) , which corresponded to the elution volumes of type II ,B-(1-2)glucan and of type I 3-(1-2)glucan after removal of nonglucosidic substituent groups (Fig. 2D) . This result indicated that a nonsubstituted P-(1-2)glucan was formed in vitro. Wild-type and mutant membranes formed in vitro a small proportion of P-(1-2)glucans that eluted from the column with a Kav of 0.09; these glucans were not observed to be formed in vivo. Total and partial acid hydrolyses of the in vitro products showed that they were P-(1-2)glucans. In addition, they were resistant to degradation by Glusulase, which suggested that they had a cyclic structure (data not shown were subjected to polyacrylamide gel electrophoresis as described previously (30) . Inner membranes of chvA mutant strains ME104 and ME66 contained higher levels of 235-kDa protein than did wild-type cells (Fig. 6A, lanes 1, 2, 7 (Fig. 8) . In strain ME42, the insertion of the lacZ gene is oriented in the same direction of transcription as is chvA, whereas in strains ME104 and ME66 the orientation is in the opposite direction (Fig. 8 ).
Inner membranes of strains A348, ME42, ME104, and ME66
were assayed for ,B-galactosidase activity as described in and accumulate an altered molecular form of cellular I-(1-2)glucan. We previously reported that avirulent mutants mapping in a nearby locus (chvB) were negative in I-(1-2)glucan synthesis because of the absence of a 235-kDa 3-(1-2)glucan protein intermediate (30) . In this paper, we have shown that chvA mutant inner membranes contained higher amounts of a 235-kDa intermediate protein than did wild-type membranes. Accordingly, mutant inner membranes formed P-(1-2)glucan in vitro at a higher rate than did wild-type membranes. However, in vivo cellular accumulation of P-(1-2)glucan was reduced by approximately 50%. Moreover, mutant cells accumulated primarily a different molecular form of ,B-(1-2)glucan (type II) that corresponded to a nonsubstituted form of the polysaccharide. Wild-type cells accumulated substituted P-(1-2) glucan (type I). Removal of nonsugar substituents from type I 3-(1-2)glucan yielded type II, which suggested that type I is a substituted form of type II. The accumulation by chvA mutants of nonsubstituted 3-(1-2)glucan may be due either to a defect in the enzymes or substrates required for the modifying reaction or to a defect in the translocation of 3-(1-2)glucan into the periplasmic space, where the modifying reactions might take place. It was proposed for the membrane-derived oligosaccharides of E. coli that modification of the polysaccharide with nonglycosidic substituents takes place in the periplasmic space (2) .
Recently, Stanfield et al. (23) reported that an R. meliloti ndvA mutant, equivalent to Agrobacterium chvA mutants, contained the 235-kDa ,B-(1-2)glucan protein intermediate but neither secreted nor accumulated 3-(1-2)glucan in vivo. Although these authors proposed, on the basis of protein homology with other export proteins, that ndvA is required for secretion of 3-(1-2)glucan, they did not rule out the possibility that the mutant was defective in the synthesis of 3-(1-2)glucan (23) . If in vivo synthesis is not affected but secretion is abolished, one would expect to observe higher levels of intracellular ,B-(1-2)glucan accumulated, which were not found.
We found that besides being defective in secretion, chvA mutants were defective in the rate of synthesis of total cyclic ,B-(1-2)glucans. Accordingly, higher levels of intracellular 3-(1-2)glucan were not expected to be found. Moreover, the mutants accumulated a nonmodified form of ,-(1-2)glucan that we suggest is the precursor of the modified wild-type ,B-(1-2)glucan. Complementation of mutants with plasmid pCD522 restored virulence and accumulation of type I 3-(1-2)glucan, which indicated that both characteristics were associated with the mutations. In vitro, wild-type and chvA mutant inner membranes formed nonmodified cyclic P- (1) (2) glucan that was identical to the nonmodified ,-(1-2) glucan accumulated in vivo by chvA mutants. These results suggest that the components required for synthesis of modified wild-type P-(1-2)glucan are missing or inactive in vitro, which reproduces the effect observed in vivo in the mutants.
The ChvA protein was proposed to be a membrane protein on the basis of its hydropathy plot (predominantly hydrophobic in the N-terminal end) and high homology to other membrane-bound transport proteins (3). We showed that inner membranes of chvA mutants were defective in a protein with an apparent molecular size of 75 kDa, similar to that predicted by sequencing data (3). Furthermore, inner membranes of chvA mutant strain ME42 contained 3-galactosidase activity, probably as a result of the formation of a fusion protein induced by the insertion of the Tn3::HoHol transposon (21) in the N-terminal end of the gene (Fig. 8) .
Since the chvA gene product is probably an inner membrane-bound protein, it may form a complex with the 235-kDa protein. As a result, absence of the ChvA protein may be responsible for the different patterns of tryptic fragments observed in chvA mutants. It was reported that other transport proteins highly homologous to the ChvA protein also form complexes with proteins encoded in the same operon (8) . Additional work will be required to firmly establish the interaction in the inner membrane of the ChvA protein with the 235-kDa protein.
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